1/13
Long-term oral vitamin E supplementation in cystic fibrosis patients: RRR-alpha-tocopherol compared with all-rac-alpha-tocopheryl acetate preparations / BM Winklhofer Roob; PE Tuchschmid; L Molinari; DH Shmerling.-- p.722-28.-- En: American Journal of Clinical Nutrition.-- 63, 5 (1996)
ADMINISTRACION ORAL   ADOLESCENCIA   ADULTO   ANTIOXIDANTES   NIÑO   INFANTE   COLESTEROL   FIBROSIS QUISTICA   RELACION DOSIS-RESPUESTA A DROGA   LACTANTE   HEPATOPATIAS   FACTORES DE TIEMPO   VITAMINA E   DEFICIENCIA DE VITAMINA E
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-4989
Tipo de Material:
Separata

    To investigate the efficacy of three different vitamin E preparations for optimizing vitamin E status in cystic fibrosis (CF patients long-term, 29 patients (aged 0.7-29.8 y) were randomly assigned to receive 400 IU of either RRR-alpha-tocopherol (A: 268 mg, n = 10) or all rac-alpha-tocopheryl acetate as a fat-soluble (B: 400 mg, n = 10) or water-miscible preparation (C: 400 mg, n = 9) and were followed for 6 wk. In the whole study group, plasma alpha-tocopherol concentrations increased from baseline (10.5 +/- 4.6 micromol/L) to 3 wk (25.7 +/- 6.5 micromol/L; P < 0.001), but not further between 3 and 6 wk; concentrations at 3 and 6 wk did not differ from those of age-matched control subjects (23.6 +/- 3.9 micromol/L). There was no significant difference in the increase from baseline to 6 wk among preparations A (17.75 +/- 8.43 micromol/L), B (14.0 +/- 9.4 micromol/L), and C (15.5 +/- 7.1 micromol/L). Because of differences in body weight, the dose administered ranged from 5.5 to 47.4 IU x kg-1 x d-1; it correlated positively with the increase in plasma alpha-tocopherol concentrations (P < 0.001). There was no significant difference in the increase in plasma alpha-tocopherol concentrations between patients with CF-associated liver disease (n = 8) who received 10.2 +/- 3.8 IU x kg-1 x d-1 and those without liver disease taking comparable doses. We conclude that CF patients can be efficiently supplemented with 400 IU/d of any one of the three vitamin E preparations and plasma values of healthy control subjects can be achieved.

Ver separata




2/13
The effect of level of protein intake in isoenergetic diets on energy utilization / WC Jr MacLean; GG Graham.-- p.1381-1387.-- En: American Journal of Clinical Nutrition.-- 32, 7 (1979)
ADOLESCENCIA   ENVEJECIMIENTO   PESO CORPORAL   CASEINAS   NIÑO   INFANTE   PROTEINAS EN LA DIETA   RELACION DOSIS-RESPUESTA A DROGA   INGESTION DE ENERGIA   METABOLISMO ENERGETICO   PROTEINAS DE LA LECHE   NITROGENO   NECESIDADES NUTRICIONALES   PROTEINAS DE PLANTAS   ALBUMINA SERICA   TRIGO
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-4271
Tipo de Material:
Separata




3/13
Serum vitamin A distribution curve for children aged 2-6 y known to have adequate vitamin A status: a reference population / H Flores; MN Azevedo; FA Campos; MC Barreto Lins; AA Cavalcanti; AC Salzano; RM Varela; BA Underwood.-- p.707-711.-- En: American Journal of Clinical Nutrition.-- 54, 4 (1991)
INFANTE   RELACION DOSIS-RESPUESTA A DROGA   AREAS DE POBREZA   VALORES DE REFERENCIA   VITAMINA A
Categoría geográfica: BRASIL  
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-4336
Tipo de Material:
Separata

Ver separata



4/13
The effect of caffeine on pregnancy outcome variables / TS Hinds; WL West; EM Knight; BF Harland.-- p.203-207.-- En: Nutrition Reviews.-- 54, 7 (1996)
ANOMALIAS INDUCIDAS POR DROGAS   ABORTO ESPONTANEO   CAFEINA   RELACION DOSIS-RESPUESTA A DROGA   RECIEN NACIDO DE BAJO PESO   RECIEN NACIDO   EMBARAZO   RESULTADO DEL EMBARAZO   FACTORES DE RIESGO   XANTINAS
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-4578
Tipo de Material:
Separata




5/13
Magnesium balance in adolescent females consuming a low- or high-calcium diet / MB Andon; JZ Ilich; MA Tzagournis; V Matkovic.-- p.950-953.-- En: American Journal of Clinical Nutrition.-- 63, 6 (1996)
ABSORCION   ADMINISTRACION ORAL   CALCIO   CALCIO EN LA DIETA   NIÑO   RELACION DOSIS-RESPUESTA A DROGA   METODO DOBLE CIEGO   HECES   MAGNESIO   NECESIDADES NUTRICIONALES   PUBERTAD   ANALISIS DE REGRESION
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-4785
Tipo de Material:
Separata

    Increasing emphasis is being placed on optimizing calcium intake during growth as a way to enhance peak bone mass. Although some studies in adults have shown that high calcium intake may negatively affect magnesium utilization, few data are available regarding the interaction of calcium and magnesium in healthy children. The purpose of our study was to measure the effect of calcium intake on magnesium balance in 26 adolescent girls (mean age 11.3 y) during a 14-d period. Subjects ate a controlled basal diet containing 667 mg Ca and 176 mg Mg. In addition to the basal diet, subjects were randomly assigned in a double-blind fashion to consume 1000 mg elemental Ca/d as calcium citrate malate or a placebo. Magnesium use did not differ between the low-calcium and high-calcium groups as measured by absorption (50% compared with 55%), urinary excretion (70 compared with 74 mg/d), and fecal excretion (88 compared with 79 mg/d). Accordingly, magnesium balance was not different in subjects consuming 667 or 1667 mg Ca/d and averaged 21 mg Mg/d for the whole study group. Magnesium balance was significantly correlated with magnesium intake (r = 0.511, P = 0.008) and magnesium absorption (r = 0.723, P < 0.001). Prediction intervals from the regression of magnesium balance on intake indicated that the current recommended dietary allowance of magnesium would result in magnesium balance > or = 8.5 mg/d in 95% of the girls. This value appears consistent with long-term accretion rates needed to account for the expansion of the total-body magnesium pool during growth. In summary, our observations support the adequacy of the current recommended dietary allowance for magnesium and indicate that alterations in magnesium utilization should not be anticipated in adolescent females consuming a high-calcium diet.-




6/13
Phenylketonuria: tyrosine supplementation in phenylalanine-restricted diets / FJ van Spronsen; M van Rijn; J Bekhof; R Koch; PG Smit.-- p.153-157.-- En: American Journal of Clinical Nutrition.-- 73, 2 (2001)
AMINOACIDOS   RITMO CIRCADIANO   DIETA   SUPLEMENTOS DIETETICOS   RELACION DOSIS-RESPUESTA A DROGA   ALIMENTOS FORTIFICADOS   INTERCAMBIO MATERNO FETAL   FENILALANINA   FENILCETONURIA   EMBARAZO   COMPLICACIONES DEL EMBARAZO   GUSTO   TIROSINA
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-4920
Tipo de Material:
Separata

    Treatment of phenylketonuria (PKU) consists of restriction of natural protein and provision of a protein substitute that lacks phenylalanine but is enriched in tyrosine. Large and unexplained differences exist, however, in the tyrosine enrichment of the protein substitutes. Furthermore, some investigators advise providing extra free tyrosine in addition to the tyrosine-enriched protein substitute, especially in the treatment of maternal PKU. In this article, we discuss tyrosine concentrations in blood during low-phenylalanine, tyrosine-enriched diets and the implications of these blood tyrosine concentrations for supplementation with tyrosine. We conclude that the present method of tyrosine supplementation during the day is far from optimal because it does not prevent low blood tyrosine concentrations, especially after an overnight fast, and may result in largely increased blood tyrosine concentrations during the rest of the day. Both high tyrosine enrichment of protein substitutes and extra free tyrosine supplementation may not be as safe as considered at present, especially to the fetus of a woman with PKU. The development of dietary compounds that release tyrosine more slowly could be beneficial. We advocate decreasing the tyrosine content of protein substitutes to approximately 6% by wt (6 g/100 g protein equivalent) at most and not giving extra free tyrosine without knowing the diurnal variations in the blood tyrosine concentration and having biochemical evidence of a tyrosine deficiency. We further advocate that a better daily distribution of the protein substitute be achieved by improving the palatability of these products.-




7/13
Response to a single oral dose of all-rac-alpha-tocopheryl acetate in patients with cystic fibrosis and in healthy individuals / BM Winklhofer Roob; PE Tuchschmid; L Molinari; DH Shmerling.-- p.717-721.-- En: American Journal of Clinical Nutrition.-- 63, 5 (1996)
ABSORCION   ADMINISTRACION ORAL   ADULTO   ANTIOXIDANTES   TRANSPORTE BIOLOGICO   NIÑO   COLESTEROL   ESTUDIO COMPARATIVO   FIBROSIS QUISTICA   RELACION DOSIS-RESPUESTA A DROGA   ERITROCITOS   LIPASA   LIPIDOS   EXTRACTOS PANCREATICOS   PANCRELIPASA   VITAMINA E   DEFICIENCIA DE VITAMINA E
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-4994
Tipo de Material:
Separata

    Biochemical vitamin E deficiency and low plasma lipids are frequent findings in patients with cystic fibrosis (CF). The response to a single oral dose of all-rac-alpha-tocopheryl acetate [100 IU (100 mg)/kg body wt] was studied over 24 h in 25 CF patients with exocrine pancreatic insufficiency and in 23 healthy individuals. Patients received pancreatic enzymes together with the vitamin E test dose. At baseline, plasma alpha-tocopherol concentrations correlated with cholesterol concentrations; both were lower in patients than in control subjects, as were erythrocyte alpha-tocopherol concentrations (all P < 0.0001). Plasma and erythrocyte alpha-tocopherol concentrations were significantly higher than baseline concentrations from 3 and 6 h onward, respectively, and peaked most frequently at 6 and 12 h, respectively, in both patients and control subjects. Maximum increases and areas under the concentration time curves for plasma alpha-tocopherol concentrations were smaller in patients than in control subjects (P < 0.0001). When ratios of plasma alpha-tocopherol to cholesterol (to correct for differences in cholesterol concentrations) or erythrocyte alpha-tocopherol concentrations were applied, patients were shown to respond as efficiently as control subjects. On the basis of these results, we recommend vitamin E supplements in doses high enough to achieve vitamin E status in CF patients well within the range of healthy individuals; these supplements should be given with appropriate amounts of pancreatic enzymes. However, for long-term supplementation much lower doses than those used in this test situation may be sufficient.




8/13
Deficiency of vitamins E and A in cystic fibrosis is independent of pancreatic function and current enzyme and vitamin supplementation / L Lancellotti; C D'Orazio; G Mastella; G Mazzi; U Lippi.-- p.281-285.-- En: European Journal of Pediatrics.-- 155, 4 (1996)
ADOLESCENCIA   ADULTO   NIÑO   INFANTE   TERAPIA COMBINADA   FIBROSIS QUISTICA   RELACION DOSIS-RESPUESTA A DROGA   ESQUEMA DE MEDICACION   LACTANTE   EXTRACTOS PANCREATICOS   INSUFICIENCIA PANCREATICA   VITAMINA A   DEFICIENCIA DE VITAMINA A   VITAMINA E   DEFICIENCIA DE VITAMINA E
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-4952
Tipo de Material:
Separata

Ver separata



9/13
Antioxidant and prooxidant properties of carotenoids / AJ Young; GM Lowe.-- pp. 20-27.-- En: Archives of Biochemistry and Biophysics.-- 385, 1 (2001)
ANTIOXIDANTES   ACIDO ASCORBICO   CAROTENOIDES   MEMBRANA CELULAR   DIETA   RELACION DOSIS-RESPUESTA A DROGA   RADICALES LIBRES   HUMANO   MODELOS QUIMICOS   OXIGENO   VITAMINA E   BETA CAROTENO
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-5152
Tipo de Material:
Separata

Ver separata



10/13
Dose-response relationship between fat ingestion and oxidation: quantitative estimation using whole-body calorimetry and 13C isotope ratio mass spectrometry / BJ Sonko; AM Prentice; WA Coward; PR Murgatroyd; GR Goldberg.-- pp. 10-18.-- En: European Journal of Clinical Nutrition.-- 55, 1 (2001)
Notas de Contenido:
Revista en estantería
ADOLESCENCIA   ADULTO   TESTS RESPIRATORIOS   CALORIMETRIA INDIRECTA   DIOXIDO DE CARBONO   ISOTOPOS DE CARBONO   ACEITE DE MAIZ   GRASAS EN LA DIETA   RELACION DOSIS-RESPUESTA A DROGA   METABOLISMO ENERGETICO   FEMENINO   HUMANO   CINETICA   LIPIDOS   LIPOLISIS   MASCULINO   DINAMICAS NO LINEALES   OXIDACION-REDUCCION   PERIODO POSPRANDIAL   FACTORES DE TIEMPO
Ubicación: Centro de Información y Documentación (CANIA)   
Tipo de Material:
Separata

    OBJECTIVE: To determine dose-dependent relationship between ingested fat and its oxidation in the immediate post-prandial period in humans. DESIGN: Subjects were randomly selected for the study at the Dunn Clinical Nutrition Centre, Cambridge, UK. Subjects ingested naturally enriched 13C corn-oil doses (range 20-140g) in a whole-body indirect calorimeter, and were studied for 8 h. Ingested fat oxidation was estimated from the subject's breath 13C enrichment and total carbon dioxide production. Total fat and carbohydrate oxidation were estimated from non-protein oxygen and carbon dioxide exchanges. Endogenous fat oxidation was estimated as the difference between total fat and ingested fat oxidation. RESULTS: The amount of fat dose oxidized was nonlinearly related to the amount ingested. On average, 25.6+/-2.7% of the mean fat dose was oxidized. A significant (r = - 0.72, P < 0.001) inverse correlation was found between the amount of fat dose and the proportion oxidized. Endogenous carbohydrate oxidation was negatively and significantly correlated to fat dose oxidized (r= -0.61, P < 0.01), but it was not correlated to endogenous fat oxidation. CONCLUSIONS: There was a nonlinear relationship between amount of fat dose and its quantity that was oxidized in the immediate post-prandial period. The inverse relationship between the size of the fat load and the proportion that was oxidized post-prandially implies increased dietary fat storage beyond about 50 g in a normal resting adult. This has important implications for 13CO2-based studies.

Ver separata




11/13
Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens / YK van Pareren; SM de Muinck Keizer Schrama; T Stijnen; TC Sas; M Jansen; BJ Otten; et.al..-- pp. 1119-25.-- En: The Journal of Clinical Endocrinology and Metabolism.-- 88, 3 (2003)
ESTATURA   NIÑO   PREESCOLAR   RELACION DOSIS-RESPUESTA A DROGA   ESTRADIOL   HORMONA DEL CRECIMIENTO   FACTOR I DEL CRECIMIENTO SIMILAR A LA INSULINA   SINDROME DE TURNER
Ubicación: Centro de Información y Documentación (CANIA)   
Solicite el material por este código: AS-6104
Tipo de Material:
Separata

    Although GH treatment for short stature in Turner syndrome is an accepted treatment in many countries, which GH dosage to use and which age to start puberty induction are issues of debate. This study shows final height (FH) in 60 girls with Turner syndrome treated in a randomized dose-response trial, combining GH treatment with low dose estrogens at a relatively young age. Girls were randomly assigned to group A (4 IU/m(2).d; approximately 0.045 mg/kg/d), group B (first year, 4 IU/m(2).d; thereafter 6 IU/m(2).d), or group C (first year, 4 IU/m(2).d; second year, 6 IU/m(2).d; thereafter, 8 IU/m(2).d). After a minimum of 4 yr of GH treatment, at a mean age of 12.7 +/- 0.7 yr, low dose micronized 17beta-estradiol was given orally. After a mean duration of GH treatment of 8.6 +/- 1.9 yr, FH was reached at a mean age of 15.8 +/- 0.9 yr. FH, expressed in centimeters or SD score, was 157.6 +/- 6.5 or -1.6 +/- 1.0 in group A, 162.9 +/- 6.1 or -0.7 +/- 1.0 in group B, and 163.6 +/- 6.0 or -0.6 +/- 1.0 in group C. The difference in FH in centimeters, corrected for height SD score and age at start of treatment, was significant between groups A and B [regression coefficient, 4.1; 95% confidence interval (CI), 1.4, 6.9; P < 0.01], and groups A and C (coefficient, 5.0; 95% CI, 2.3, 7.7; P < 0.001), but not between groups B and C (coefficient, 0.9; 95% CI, -1.8, 3.6). Fifty of the 60 girls (83%) had reached a normal FH (FH SD score, more than -2). After starting estrogen treatment, the decrease in height velocity (HV) changed significantly to a stable HV, without affecting bone maturation (change in bone age/change in chronological age). The following variables contributed significantly to predicting FH SD score: GH dose, height SD score (ref. normal girls), chronological age at start of treatment, and HV in the first year of GH treatment. GH treatment was well tolerated. In conclusion, GH treatment leads to a normalization of FH in most girls, even when puberty is induced at a normal pubertal age. The optimal GH dosage depends on height and age at the start of treatment and first year HV.




12/13
Monitoreo de la farmacoterapia en la unidad de cuidados intensivos pediátricos = Therapeutic drug monitoring in the pediatric intensive care unit / MD Reed; JL Blumer.-- pp. 1219-33.-- En: Clínicas Pediátricas de Norteamérica.-- 6 (1994)
Notas de Contenido:
Revista en estanteria
ADOLESCENTE   NIÑO   ENFERMEDAD CRITICA   RELACION DOSIS-RESPUESTA A DROGA   UNIDADES DE CUIDADO INTENSIVO PEDIATRICO   FARMACOCINETICA   FARMACOLOGIA
Ubicación: Centro de Información y Documentación (CANIA)   
Tipo de Material:
Separata

    Drugs are administered in the pediatric intensive care unit using either a target-effect or a target-concentration strategy. In the former, drug dose is escalated until the predetermined target-effect is achieved, no further pharmacologic effect is obtained with incremental increases in dose, or toxicity supervenes. When the target-concentration strategy is used, drug therapy is adjusted to achieve serum/plasma drug concentrations within an accepted therapeutic range. This strategy does not recognize interindividual differences in drug responsiveness. Therapeutic drug monitoring in the pediatric intensive care unit is further confounded by the limited data available concerning the effects of the other technologies used on drug disposition and the paucity of information related to therapeutic agents in pediatric patients. Clearly therapeutic drug monitoring in the pediatric intensive care unit is a daunting challenge.




13/13
Assessment of vitamin A status with the relative-dose-response test in Peruvian children recovering from pneumonia / CB Stephensen; LM Franchi; H Hernandez; M Campos; A Colarossi; RH Gilman; et.al..-- pp. 1351-7.-- En: American Journal of Clinical Nutrition.-- 76, 6 (2002)
Notas de Contenido:
Material no impreso
PROTEINA C-REACTIVA   RELACION DOSIS-RESPUESTA A DROGA   NEUMONIA BACTERIANA   NEUMONIA VIRAL   VITAMINA A   METODO DOBLE CIEGO   PREESCOLAR   LACTANTE
Ubicación: Centro de Información y Documentación (CANIA)   
Tipo de Material:
Separata

    BACKGROUND: The relative-dose-response (RDR) test is used to identify subjects with marginal liver vitamin A stores, but its use has not been evaluated during episodes of infection. OBJECTIVE: The objective was to assess, with the RDR test, the vitamin A status of children recovering from pneumonia. DESIGN: As part of a double-blind, placebo-controlled clinical trial of high-dose vitamin A supplements among children hospitalized with pneumonia in Lima, Peru, we examined the association of treatment group, nutritional status, severity of disease, and induction of the acute phase response [on the basis of serum C-reactive protein (CRP)] on serum retinol and the RDR test. RESULTS: Serum retinol was low at admission and increased significantly in both the vitamin A and placebo groups during recovery. Serum CRP had a significant, inverse association with retinol at both admission and discharge. Serum retinol and CRP concentrations never differed significantly between the treatment groups. Among subjects with CRP ] or =10 mg/L, 21% in the vitamin A group and 20% in the placebo groups (P = 0.83) had a positive RDR test result. Among subjects with CRP [10 mg/L, 56% in the placebo group but only 6% in the vitamin A group had positive RDR test results (P = 0.002).......continua.

Ver separata





13 Registros recuperados

Presentar con el formato: 

Ver selección       Limpiar selección